GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Total Current Assets

JW (Cayman) Therapeutics Co (HKSE:02126) Total Current Assets : HK$1,167.6 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. JW (Cayman) Therapeutics Co's total current assets for the quarter that ended in Dec. 2023 was HK$1,167.6 Mil.

JW (Cayman) Therapeutics Co Total Current Assets Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Total Current Assets Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Assets
Get a 7-Day Free Trial 290.81 3,138.27 2,320.42 1,658.51 1,167.59

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 2,320.42 1,918.48 1,658.51 1,466.98 1,167.59

JW (Cayman) Therapeutics Co Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

JW (Cayman) Therapeutics Co's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=1100.242+18.451+38.039+10.859
=1,167.6

JW (Cayman) Therapeutics Co's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=1100.242+18.451+38.039+10.859
=1,167.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

JW (Cayman) Therapeutics Co  (HKSE:02126) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

JW (Cayman) Therapeutics Co's Liquidation Value for the quarter that ended in Dec. 2023 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=1100.242-505.609+0.75 * 0+0.5 * 38.039
=613.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co Total Current Assets Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co (HKSE:02126) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Total Current Assets
Comparable Companies
HKSE:02197 HKSE:02185 HKSE:06996 HKSE:06998 HKSE:03681 HKSE:01228 HKSE:02142 HKSE:09939 HKSE:01875 HKSE:00690 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
JWCTF:USA
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
Website
https://www.jwtherapeutics.com
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Executives
Li Dan 2202 Interest of your spouse
Li Yiping James 2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd. 2501 Other
Bristol-myers Squibb Company 2201 Interest of corporation controlled by you
Celgene Corporation 2201 Interest of corporation controlled by you
Juno Therapeutics, Inc. 2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd. 2501 Other

JW (Cayman) Therapeutics Co (HKSE:02126) Headlines

No Headlines